Scott Richards brings over 35 years of international experience in the pharmaceutical industry to his role as Chief Executive Officer of Envision Sciences. Scott has diverse global pharma experience, holding various leadership positions in multiple international jurisdictions, including as Managing Director and CEO of ASX-listed Mayne Pharma Limited from 2012 to 2022. Scott also served as President for Europe, Middle East, and Africa, and later as President of Global Commercial Operations for Mayne Pharma Limited. He also joined the Group Management Board of Actavis, overseeing global injectable/hospital business operations. Scott's earlier career includes significant roles at FH Faulding and Co, where he led operations in Asia Pacific, and several years in the United States focusing on business development and portfolio management.

John specializes in clinical systems development, spanning the research, acute care & diagnostics settings.  He has over fifteen years of experience delivering advanced technology solutions for oncology diagnostics including digital pathology, artificial intelligence & next-generation sequencing (NGS).  John is a subject-matter expert in healthcare data / integration & has been active in shaping standards for HL7 and HHS ONC. 

Prior to joining Envision, John has held leadership positions at Neogenomics, BioReference (Opko Health) & CareEvolve (Ellkay). He has a BS in Information Management from the University of Scranton.

Seong brings to Envision Sciences 16 years of experience in diagnostics including roles in major global diagnostic companies. He specializes in the development of diagnostic technology, business development and commercialization. He has also worked for the Boston Consulting Group and his skills include business analysis, molecular diagnostics, commercial solutions and global business development including solutions for personalized medicine. Seong has a B Eng (Hons) from Melbourne University and an MBA from Berkeley.

Andrew qualified in Laboratory Medicine and was State-registered in the UK.  He has a PhD in pathology/immunology (UCL) and several years post-doctoral medical research experience.  Andrew was Chief Scientific Officer of TransBio Ltd for seven years prior to becoming the Biotechnology Strategic Advisor with Bio-Link, Australia (2014 – 2019), and subsequently Head of Innovation at Exopharm Ltd (ASX:EX1) in early-2019 to mid-2021. Andrew’s roles included diagnostic pathology, coordination of biomarker discovery and validation programs, project management, intellectual property management and licensing.

His role at Envision Sciences utilises his scientific and commercial experience gained over several decades encompassing diagnostic pathology, academic research, and corporate biotechnology.

He has served on the editorial board of journals Cell Biology Insights and Journal of Drug Discovery and Delivery and was a member of the NHMRC Research Translational Faculty.

Siew Mei has over 18 years of combined experience in law and finance.

Over the last 12 years, Siew Mei has specialized in law advising both private and public entities on various legal matters with a strong emphasis on compliance and regulatory issues, particularly in the areas of equity capital markers, mergers and acquisitions (M&A), corporate transactions and corporate governance. Prior to her legal career, Siew Mei worked as an accountant specializing in business services work, during which time she gained valuable insights into financial operations and strategic planning. 

Siew Mei holds a Bachelor of Laws from the Queensland University of Technology and a Bachelor of Commerce and Administration from the University of Victoria, Wellington NZ.

Gareth has over 25 years of pharmaceutical experience spanning drug and clinical development, portfolio strategy, pre-launch commercialization, business development and licensing as well as on-market commercial responsibility. Having worked in a range of therapeutic areas, this development and commercialization expertise includes a range of products and technologies, with broad multinational experience from time working in Australia, USA, Europe and Asia Pacific.

 Gareth’s pharmaceutical career started with AstraZeneca in the UK and Sweden, before moving to the Australian biotech sector. After gaining additional experience with generic injectable products at Hospira, he moved to Mayne Pharma, undertaking successive commercial leadership roles with increasing executive responsibilities in Australia and the USA. Most recently he was responsible for the strategic development and commercialization of a private biotech company’s drug candidate assets as well as leading all Corporate and Business Development activities.

 Gareth completed a PhD in Chemistry at the University of Bristol in the UK and was awarded a Royal Society Fellowship to undertake postdoctoral research at the University of New South Wales, Sydney.

Litsa has a PhD in Cellular Biology and Virology from the University of Adelaide and 30 years’ experience in medical research, with a primary focus on cell biology and disease and drug discovery. Litsa is experienced in product translation from research to clinical applications and, in previous roles, was involved in driving biomarker discovery and validation programs, overseeing R&D projects, and managing intellectual property. At Envision Sciences, Litsa applies her extensive scientific and commercial expertise to manage the company’s R&D projects and initiatives, ensuring they align with Envision Sciences’ overall strategic objectives and contribute to its growth and innovation in the field.

John brings over 35 years of extensive business experience including as the Chairman of the Higgins Group of Companies. This privately-owned group invests and runs companies in Australia, Europe and North America with an increased focus on Medical Research in Cancer and Traumatic Brain Injuries.

John is also respected and recognized for his distinguished service to the community through philanthropic contributions to education, culture, social welfare, child cancer support organizations and business. He is a Life Member of the National Gallery of Victoria, Australia and serves on its Foundation Board. He is also a Director of Camp Quality, an Australian children's cancer charity, for the past 14 years.

Doug is the leader of the Mechanisms in Cell Biology and Disease Research Group at the University of South Australia Cancer Research Institute.

Professor Brooks focus includes biomarker development for prostate and a number of other cancers, including work on biomarkers for tissue histology, the early detection of cancer and companion diagnostics. Doug has over 30 years experience in medical research and is also a Research Professor in Molecular Medicine. His initial research training was in Immunology with a focus on cancer research, involving the immunochemistry of cell surface antigens.

Charles joined Liridon Diagnostics with over 30 years in C-Suite positions across the diagnostic and pharmaceutical industries.  He was the founder and CEO of GenCare Biomedical Research Corporation, the first dedicated Oncology laboratory in the United States. He sold this laboratory to BioReference Laboratories in 1995 where he was responsible for organic revenue growth of more than one billion dollars over 22 years.

His major accomplishments include developing and implementing industry leading programs in the areas of Oncology, Women’s Health and Genetics, with an emphasis on prostate, colon and ovarian cancers.  Charles was responsible for sales and marketing activities of OPKO Health’s 4K Score test after their acquisition of BioReference Laboratories in 2014 (NYSE – “OPK”).

Dr Dhingra was appointed as Corporate and Strategic R&D advisor in 2020. He was Head of the Oncology Leadership Team and Head of Oncology Clinical Development at Roche for 9 years. Prior to that he held senior physician appointments with Eli Lilly and Company and the MD Anderson Cancer Centre.

Kapil has been directly involved as a board member in multi-billion-dollar acquisitions by major pharmaceutical companies in radioligand and diagnostics in oncology especially prostate cancer. Kapil was a director of Exosome Diagnostics for 5 years before it was acquired for $575M. Exosome Dx develops urine based genomic early detection tests for prostate cancer.

Peter has led a range of teams in his career and is an experienced leader and strategic planner. He has led the development and strategic direction of the therapeutics company PresSura Neuro for over 5 years and brings all the experience of development, clinical trials and an expertise in international industry science networks to Liridon Diagnostics (formerly Envision Sciences). He is experienced at capital raising across a number of industries in Australia and overseas, and his skill sets are well-suited to lead the development and commercial goals set for Liridon.

Peter is an experienced public company executive and has held director positions in various companies and industry sectors including in energy, mining services and medical therapeutics. His recent appointments include being chairman of PresSura Neuro (therapeutics for traumatic brain injury and concussion), executive chairman of Austin Engineering (ASX Code:ANG) in 2016. Peter co-founded Liridon Diagnostics in 2016. 

Edwin Hendrick joins Envision with over 30 years of experience in both diagnostics, clinical pathology and laboratory services and equipment. After beginning his career in sales with Abbott Diagnostics he has achieved a strong track record of building and growing businesses. In his most recent position at PreludeDx, which offers DCISionRT, a predictive and prognostic test for DCIS management, he served as Chief Commercial Officer. In this role he helped manage all aspects of commercial operations, including managed care, marketing and sales.

Mr. Hendrick also served at GenomeDx, now Decipher Biosciences, where he developed the company’s commercial strategy and launched its initial commercial offering. In his role as Executive Vice President, Sales and Marketing of PLUS Diagnostics, Mr. Hendrick led the company’s transformation from a regional laboratory generating $10 million in annual revenues to a national anatomic pathology leader achieving more than $100 million in annual revenues. PLUS Diagnostics’ growth culminated in the company’s successful sale to Miraca Life Sciences.

Mr. Hendrick also served as an executive with US Labs, a start-up anatomic pathology company, which ended in its purchase by LabCorp. Prior to US Labs, Mr. Hendrick led sales and marketing for Ventana Medical Systems, a medical device and reagent business, now a member of the Roche Group. He received his Bachelor of Arts in Advertising from the University of Kentucky.

Dr. Stone has over 25 years of experience in developing molecular diagnostics. Most recently, he was SVP for R&D at DermTech were he directed research and development of molecular tests to support clinical management of dermatology patients. He was also a member of the executive team and was responsible for company-wide scientific leadership. Prior to DermTech, he was VP of Kidney Care at CareDx. His groups were responsible for the research and development of molecular tests including AlloMap, HistoMap and UroMap. AlloMap and UroMap were intended to non-invasively diagnose organ rejection. Histomap provides molecular information to augment histological diagnosis of rejection after biopsy. He also spent over 25 years at Myriad Genetics in positions of increasing responsibility. His final role was as VP of Cancer Genomics where his group was responsible for the development of a molecular prognostic test for newly diagnosed prostate cancer (Prolaris). Also while at Myriad, he was involved in the discovery and characterisation of several important cancer genes including BRCA1 and p16. He received his Ph.D. in Genetics from the University of Minnesota in 1993. He has authored or co-authored over 50 peer-reviewed publications and 10 US patents.